Ivanyi, P., Bullement, A. orcid.org/0000-0001-7091-0972, Botticelli, A. et al. (7 more authors) (2025) Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy. Future Oncology, 21 (14). pp. 1779-1786. ISSN: 1479-6694
Abstract
Aims: To investigate the differences in clinical outcomes and costs for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) with a combined positive score (CPS) of 1–19, with pembrolizumab ± chemotherapy or a cetuximab-containing regimen (CCR) in Italy.
Methods: A naïve indirect treatment comparison was conducted, and outcomes were incorporated into a newly developed cost-utility model. Inputs were derived from clinical trials, technology appraisal reports, and published literature. Scenario analyses were undertaken to explore key areas of uncertainty.
Results: Across the comparisons of pembrolizumab ± chemotherapy versus CCRs, incremental life-years ranged from − 0.502 to 0.155, while incremental quality-adjusted life years (QALYs) ranged from − 0.379 to 0.085. In some scenarios, CCRs dominated pembrolizumab ± chemotherapy (i.e. more QALYs at lower costs). In others, CCRs yielded similar estimates of QALYs at lower costs.
Conclusion: CCRs are likely to represent a comparable or more effective treatment option compared to pembrolizumab ± chemotherapy. Model results consistently demonstrated that CCRs are a cost-effective treatment strategy. CCRs remain a relevant treatment option for R/M SCCHN and a CPS of 1–19, for whom a targeted, patient-focused approach is warranted.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
Keywords: | Humans; Head and Neck Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Treatment Outcome; Quality-Adjusted Life Years; Cost-Benefit Analysis; Italy; Antibodies, Monoclonal, Humanized; Cetuximab; Squamous Cell Carcinoma of Head and Neck |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > ScHARR - Sheffield Centre for Health and Related Research |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 06 Aug 2025 14:29 |
Last Modified: | 06 Aug 2025 14:29 |
Status: | Published |
Publisher: | Informa UK Limited |
Refereed: | Yes |
Identification Number: | 10.1080/14796694.2025.2503667 |
Related URLs: | |
Sustainable Development Goals: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:230143 |
Download
Licence: CC-BY-NC-ND 4.0